The Registry study enrolment is now closed for new participants. Thank you to all that contributed to the study.
The effects of a particular medicine on the health of an unborn baby are often unknown because pregnant women are not usually included in clinical research studies to test a potential new medicine. Pregnancy registries aim to collect information that could help women and their healthcare providers make more informed decisions about using a particular medicine during pregnancy in the future.
The OCREVUS Pregnancy Registry is a global registry for women with MS who are pregnant and have or have not received OCREVUS (ocrelizumab). The purpose of this pregnancy registry is to learn more about the health of pregnant women who have or have not received ocrelizumab and the health of their babies. This will be done by monitoring participants throughout their pregnancy, followed by monitoring the health of their babies until they are at least 12 months old.
Because of this registry, pregnant women who are exposed to ocrelizumab in the future may have more information about how their pregnancies and babies may or may not be affected.
By clicking through the website, we understand this means you have accepted our cookies.